5 Key Takeaways

• 1

  In the phase 3 DAYBREAK trial, 667 treatment-naïve patients with neovascular age-related macular degeneration received tarcocimab, tabirafusp-ted, or aflibercept.

• 2

  At weeks 40, 44, and 48, tarcocimab produced a mean gain of 7.2 ETDRS letters versus 7.6 with aflibercept, meeting the noninferiority endpoint (P = .0007).

• 3

  By the first year, 54% of tarcocimab-treated patients reached a 24-week dosing interval, and the median number of postloading injections was 1 versus 5 with aflibercept.

• 4

  Tabirafusp-ted produced a mean 6.3-letter gain versus 7.6 with aflibercept and met noninferiority for retinal drying, with central subfield thickness reductions of 131 μm and 138 μm.

• 5

  Kodiak plans to submit a mult indication biologics license application for tarcocimab to the FDA later this year; DAYBREAK will continue through week 96.